StocksMedium•24 September 2026•
1 min read
Trio-Tech Shares Plunge 36% Despite 72% Revenue Growth Driven by AI Demand
Key Facts
1Trio-Tech shares fell 36.6% despite reporting 72% revenue growth driven by AI and automotive semiconductor demand.
2Artelo Biosciences shares declined 29.5% following a provisional patent application for an obesity compound.
3Jaguar Health shares dropped 21% due to equity dilution concerns following debt-for-equity exchange agreements.
Trio-Tech shares fell 36.6% on high trading volume, despite the company reporting 72% revenue growth for fiscal 2026 driven by robust demand in the AI and automotive semiconductor markets. Financial Modeling Prep reported that the decline occurred alongside significant sell-offs across the biotechnology and semiconductor sectors affecting several small-to-mid cap firms.
TRT closed at $11.45 on September 23, 2026, while Artelo Biosciences declined 29.5% to close at $7.31 on the same date following a provisional patent application for an obesity compound. Additionally, Jaguar Health shares dropped 21% to close at $8.91 on September 23, 2026, as investors reacted to equity dilution concerns stemming from debt-for-equity exchange agreements.